

**DCAT**

# TOP Industry NEWS

***BUSY WEEK?** Here are the  
TOP INDUSTRY NEWS stories  
you might have missed, as  
selected by DCAT Editorial  
Director Patricia Van Arnum.*

More successful NDA approvals  
than any other. Delivered.

**Patheon**  
A HEALTHIER WORLD. DELIVERED.

## **1. J&J Completes \$30-Billion Buy of Actelion**

Johnson & Johnson (J&J) has completed its \$30-billion acquisition of Actelion, a Swiss pharmaceutical company specializing in products for treating pulmonary arterial hypertension. Actelion will now become part of the Janssen Pharmaceutical Companies of Johnson & Johnson. [Read More](#)

## **2. Pfizer Gets CRL on Manufacturing Issues for Epoetin Alfa Biosimilar**

Pfizer has received a Complete Response Letter (CRL) from the FDA regarding its biologics license application for its proposed epoetin alfa biosimilar over manufacturing issues at the company's facility in McPherson, Kansas. [Read More](#)

## **3. FDA To Hold Public Meeting in July on Generic Drug Review Process**

The FDA will hold a public meeting on July 18, 2017 to discuss ways to improve the generic-drug review process as a means to create a broader understanding of the interplay between the existing legal and regulatory framework, available incentives and marketplace practices, and consumer access to generic drugs. [Read More](#)

## **4. Lubrizol Corporation Announces \$60-Million Investment on Expansions**

Lubrizol Corporation has announced a \$60-million investment in its LifeSciences business, focusing on new product solutions, capacity expansion, and additional cGMP manufacturing for its excipients, polymers, drug formulation and manufacturing, and medical device contract manufacturing capabilities. [Read More](#)

## **5. European Commission Approves Novartis' Biosimilar of Roche's MabThera**

The European Commission has approved from Sandoz, the generics arm of Novartis, Rixathon, a biosimilar referencing Roche's top-selling drug MabThera, a drug to treat cancer and autoimmune diseases. MabThera/Rituxan had 2016 sales of CHF 7.3 billion (\$7.48 billion). [Read More](#)

## **6. Private Equity Firm Pamplona Capital to Acquire CRO Parexel for \$5 Billion**

Pamplona Capital Management, an investment firm, has agreed to acquire Parexel, a contract research organization, for \$5 billion. The deal would take the now publicly traded Parexel private. [Read More](#)

## **7. Takeda Completes Construction of Solid Dosage Manufacturing**

## Facility

Takeda Pharmaceutical Company has completed the construction of a new EUR-100 million (\$111 million) solid-dosage manufacturing facility at its site in Oranienburg, Germany. [Read More](#)

## **8. Merck KGaA Creates New Immuno-Oncology Company iContura**

Merck KGaA's corporate venture arm has created iContura, an immuno-oncology spin-out company based in Geneva, Switzerland. The corporate ventures fund of Merck KGaA will manage the investment and will be represented on iContura's board of directors. [Read More](#)

## **9. FDA OKs Adamis' Competitor to Mylan's EpiPen**

Adamis Pharmaceuticals, a specialty biopharmaceutical company, has received FDA approval for its epinephrine injection prefilled single-dose syringe for the emergency treatment of allergic reactions (Type I) including anaphylaxis. The product will compete with Mylan's EpiPen, an auto-injector-based epinephrine product. [Read More](#)

## **10. Eli Lilly Expands Biotechnology Center in San Diego**

Eli Lilly has completed a \$90-million expansion of its Biotechnology Center in San Diego, California. The expansion will support the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neurodegeneration and the emerging area of pain. [Read More](#)

***The DCAT organization is happy to provide this service to its members each Friday.  
Have a great weekend!***

### ***About Top Industry News***

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599  
[www.dcat.org](http://www.dcat.org)

Drug, Chemical, & Associated Technologies Association, One Union Street,  
Suite 208, Robbinsville, NJ 08691

SafeUnsubscribe™ {recipient's email}

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by [mailmanager@dcat.org](mailto:mailmanager@dcat.org)